FDA Approves Aeterna Zentaris’ IND Application for Doxorubicin

Aeterna Zentaris announced that the FDA has approved the company’s Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone or LHRH receptor positive urothelial or bladder cancer.
RTTNews